Industrial Policy & Trade Monitor· 2662 actions· ✨ 89 recent

On 8 May 2026 China's National Health Commission released a public consultation draft proposing material amendments to the 2023 Implementation Rules for the Administrative Regulations on Human Genetic Resources, with a comment deadline of 7 June 2026. The draft narrows the statutory "foreign party" definition to a bright-line 50% equity/voting threshold (excluding VIE-structured entities), restricts "HGR Information" strictly to nucleic-acid sequence data (excluding clinical, imaging, and metabolic data), removes the separate Article 37 security-review requirement for sensitive HGR datasets, and introduces a same-day or next-working-day fast-track confirmation for international clinical trials not involving HGR information export.

On 9 December 2025, Saudi Arabia's Local Content & Government Procurement Authority (LCGPA) issued the December 2025 batch expansion of its Mandatory List — a binding instrument requiring government entities, state-owned enterprises, and sub-contractors to source listed products exclusively from Saudi domestic manufacturers meeting the LCGPA-defined local-content threshold. The December 2025 expansion brings the list to approximately 1,444 national products across 16 sectors, effective 1 March 2026, with LCGPA targeting a total of approximately 2,000 products by end-2026. The Mandatory List operationalises the demand-side layer of Saudi Arabia's Vision 2030 / National Industrial Strategy (NIS) industrial-policy stack, directly restricting foreign-supplier access to Saudi annual government-procurement budgets estimated at SAR 500 billion+ across central government, Aramco, PIF-portfolio entities, Ma'aden, SEC, STC, Saudi Post, and Saudi Railway.

On 27 July 2025, President Trump and European Commission President Ursula von der Leyen reached political agreement at Turnberry, Scotland, on a Framework Agreement on Reciprocal, Fair and Balanced Trade. The framework was formalised in a Joint Statement published on 21 August 2025 by the White House and DG TRADE. The deal establishes a 15% all-inclusive (MFN + Section 232) US tariff ceiling on the vast majority of EU originating goods — including autos, pharmaceuticals, semiconductors, lumber, and chemicals — replacing the threatened 20-30% reciprocal tariff trajectory under EO 14257 (April 2025). Steel and aluminium are excluded from the 15% ceiling and remain at the 50% Section 232 rate pending negotiation of a quota solution. In return, the EU commits to: (i) eliminate tariffs on all US industrial goods, (ii) preferential market access for a wide range of US agricultural and seafood products, (iii) suspension of its rebalancing countermeasures under Reg 2025/778 (suspension effective 7 August 2025), (iv) expected energy offtake of $750bn (LNG, oil, nuclear) through 2028, (v) at least $40bn in US AI chip purchases, and (vi) facilitation of $600bn in additional EU corporate investment into the US through 2028. Effective from 1 September 2025, the US applies MFN-only treatment (no 15% top-up) to: aircraft and parts, generic pharmaceuticals and ingredients, chemical precursors, cork, and certain unavailable natural resources. The framework is not legally binding but anchors the bilateral architecture; it is the largest-economy ART-programme deal alongside US-UK, US-Japan, US-Korea, US-Taiwan, and US-Indonesia.

Bpifrance, France's state-owned public investment bank, took a 1.8% equity stake with board representation in Opella — the Sanofi-spun-off consumer healthcare unit that makes Doliprane (paracetamol) and other OTC brands — as part of the closing of Sanofi's sale of a 50% controlling stake to US private equity firm Clayton, Dubilier & Rice (CD&R). Sanofi retains 48.2%. The stake was widely read domestically as a state sovereignty guarantee attached to a politically contentious foreign takeover of a company regarded as critical to French medicine supply security.

Loi n° 22-18 du 24 juillet 2022 relative à l'investissement (Journal Officiel de la République Algérienne n° 50 du 28 juillet 2022) is Algeria's first comprehensive investment-code overhaul since Ordonnance 01-03 du 20 août 2001 and its 2016 Loi 16-09 amendment. The law replaces the legacy framework, codifies a liberalised FDI regime — retaining 51% Algerian-equity floors only for strategic sectors (hydrocarbons extraction, mining extraction, military/security) — creates the Agence Algérienne de Promotion de l'Investissement (AAPI) as the new single-window FDI-promotion agency and the Conseil National de l'Investissement (CNI) chaired by the Premier Ministre, and defines three investment regimes: Régime des Secteurs, Régime des Zones (Sud + Hauts-Plateaux territorial incentives), and the Régime Structurant for large-scale strategic projects ≥ DZD 2bn (~USD 15M) that attract negotiated multi-pillar fiscal, customs, parafiscal, and social-contribution incentive packages. Eight implementing décrets exécutifs n° 22-296 through 22-303 were published in JORADP n° 60 du 18 septembre 2022, operationalising governance, incentive matrices, the digital Registre National des Investissements, and dispute-resolution architecture.